Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States
During the 2023-2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety.
Authors
- James A. Mansi (ORCID: https://orcid.org/0000-0001-7650-6778)
- David Martin (ORCID: https://orcid.org/0000-0003-4517-0380)
- Tianyu Sun (ORCID: https://orcid.org/0000-0002-3996-1381)
- Mitra Yousefi (ORCID: https://orcid.org/0000-0001-6016-3424)
- Daina B. Esposito (ORCID: https://orcid.org/0000-0003-2894-0523)
- Tianyi Lu (ORCID: https://orcid.org/0000-0001-8410-9051)
- Amanda Wilson (ORCID: https://orcid.org/0000-0003-4430-560X)
- Elisha Beebe (ORCID: https://orcid.org/0009-0006-4921-7827)
- Neloufar Rahai (ORCID: https://orcid.org/0000-0003-1536-482X)
- Katherine E. Mues
- Ekkehard Beck
- Andre B. Araujo (ORCID: https://orcid.org/0000-0002-5967-4806)
- Priya Govil
- Hagit Kopel
- Astra Toyip
- Michelle Skornicki (ORCID: https://orcid.org/0000-0002-2594-2569)
- B. Conroy
- Morgan A. Marks
- Rohan Shah
Institutions
- Aetion (United States) (US)
- Moderna Therapeutics (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1007/s40121-024-01091-1
- Citations
- 15
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 5.84
Funders
- Moderna